Personalizing Standard Chemotherapy And A Potential New Combination Treatment Strategy
This article was originally published in Start Up
Executive Summary
A recent report shows that some cancer cells may be more sensitive to chemotherapy because their mitochondria are primed to undergo programmed cell death. An assay that identifies the start of the process could help optimize the use of traditional chemo. And novel agents not potent enough to be used against tumors on their own could selectively prime tumors in this way as part of combination therapy.